弥漫内生型脑干胶质瘤的治疗现状
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v4i4.5440
Abstract
弥漫内生型脑干胶质瘤(DIPG)是好发于儿童脑干部位的高度异质性脑肿瘤。此类肿瘤手术难度大且预后较差,常规化疗方案对肿瘤治疗无效,放疗同时无法延长患儿的有效生存期,因此患儿预后极差,有效生存期短。同时,由于脑干部位严密的血脑屏障的存在,很大程度上限制了药物治疗的效果。近年来随着对DIPG病理机制的深入研究以及新型给药方式的发展,针对DIPG的新兴疗法已取得了阶段性的进展。本文综述了包括DIPG的分子病理学改变、新型小分子药物以及新型给药方法等在内的DIPG研究现状,为提出改善DIPG患者预后治疗方案提供思路及参考。
Keywords
弥漫内生型脑干胶质瘤；病理学改变；药物递送
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] 中华医学会神经外科学分会肿瘤学组,脑干胶质瘤综合诊疗中国专家共识编写委员会.脑干胶质瘤综合诊疗中国专家共识.中华神经外科志,2017,3(33):16.
[2] R K, FB C. Management of diffuse pontine gliomas in children:recent developments.Paediatric drugs.2013,15(5):351 -362.
[3] A P, R H, MA M, et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Naturemedicine.2017,23(4):493-500.
[4] Schroeder KM, Hoeman CM, Becher OJ. Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology. Pediatr Res. 2014, 75(1-2):205-209.
[5] CS G, Y T, N T, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nature medicine. 2015,21(6):555-559.
[6] D C, KR T, NG O, et al. ACVR1ALK2 inhibitors display beneficial effects in preclinical models of mutant diffuse intrinsic pontine glioma. Communications biology. 2019;2:156.
[7] Y S, Y S, K Y, et al. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma. EBioMedicine. 2019;43:171-179.
[8] YL W, UB M, M S, et al. Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells. Translational oncology.2017;10(2):221-228.
[9] Wang Z, Xu C, Diplas BH, et al. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib. Mol Cancer Res. 2020;18(7):968-980.
[10] Lin GL, Wilson KM, Ceribelli M, et al. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci Transl Med. 2019;11(519).
[11] Wu H, Lu H, Xiao W, et al. Sequential Targeting in Crosslinking Nanotheranostics for Tackling the Multibarriers of Brain Tumors. Advanced materials (Deerfield Beach, Fla). 2020;32(14):e1903759.
[2] R K, FB C. Management of diffuse pontine gliomas in children:recent developments.Paediatric drugs.2013,15(5):351 -362.
[3] A P, R H, MA M, et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Naturemedicine.2017,23(4):493-500.
[4] Schroeder KM, Hoeman CM, Becher OJ. Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology. Pediatr Res. 2014, 75(1-2):205-209.
[5] CS G, Y T, N T, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nature medicine. 2015,21(6):555-559.
[6] D C, KR T, NG O, et al. ACVR1ALK2 inhibitors display beneficial effects in preclinical models of mutant diffuse intrinsic pontine glioma. Communications biology. 2019;2:156.
[7] Y S, Y S, K Y, et al. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma. EBioMedicine. 2019;43:171-179.
[8] YL W, UB M, M S, et al. Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells. Translational oncology.2017;10(2):221-228.
[9] Wang Z, Xu C, Diplas BH, et al. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib. Mol Cancer Res. 2020;18(7):968-980.
[10] Lin GL, Wilson KM, Ceribelli M, et al. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci Transl Med. 2019;11(519).
[11] Wu H, Lu H, Xiao W, et al. Sequential Targeting in Crosslinking Nanotheranostics for Tackling the Multibarriers of Brain Tumors. Advanced materials (Deerfield Beach, Fla). 2020;32(14):e1903759.
Copyright © 2022 单绍波
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License